Search

Recently, a North American genome-wide association study identified three novel gene variants in PHOX2B, NCF4, and FAM92B as well as one single nucleotide polymorphisms (SNP; rs224136) in the intergenic region on chromosome 10q21.1 as being associated with Crohn's disease (CD). However, their influence on European CD patients as well as ulcerative colitis (UC) is unknown. Therefore we aimed to replicate these novel CD susceptibility variants in a large European cohort with inflammatory bowel disease and analyzed potential gene-gene interactions with variants in the NOD2/CARD15, IL23R, and ATG16L1 genes.Genomic DNA from 2,833 Caucasian individuals including 854 patients with CD, 476 patients with UC, and 1,503 healthy unrelated controls was analyzed for SNPs in PHOX2B (rs16853571), NCF4 (rs4821544), and FAM92B (rs8050910), including rs224136 on chromosome 10q21.1.In our study population, no association of PHOX2B (P=0.563), NCF4 (P=0.506), FAM92B (P=0.401), and rs224136 (P=0.363) with CD was found. Similarly, none of these SNPs was associated with UC. In contrast, all analyzed SNPs in NOD2/CARD15, IL23R, and ATG16L1 were strongly associated with CD with P values ranging from 5.0x10(-3) to 1.6x10(-22), but there was no epistasis with polymorphisms in PHOX2B, NCF4, FAM92B, and rs224136.In contrast to the North American population, PHOX2B, NCF4, FAM92B, and rs224136 are not associated with CD in the European population, whereas NOD2/CARD15, IL23R, and ATG16L1 are strongly associated with CD in both the North American and European populations, confirming these three genes as major CD susceptibility genes in Caucasian populations.

Toll-like receptors (TLRs) play an important role in the recognition of microbial molecular patterns of infectious and commensal bacteria and their expression in various tissues including the intestinal epithelium orchestration of the innate and adaptive immune defense mechanisms. Changes in the TLR signaling pathways due to host genetic predispositions may turn a physiological response into a pathological situation including failure of bacterial clearance and development of chronic inflammation. The aim of this study was to characterize the role of TLR2 or TLR4 deficiency in epithelial cell stress responses under noninflamed and inflamed conditions using TLR-deficient mice and TLR(-/-) cross-bred IL-10-deficient mice as a model for genetically driven experimental colitis. Primary intestinal epithelial cells (IEC) were isolated from specific-pathogen-free wild-type, TLR2-, TLR4-, IL-10-, IL-10XTLR2- and IL-10XTLR4-deficient mice at the age of 1, 8, and 16 weeks. Histopathological analysis showed absence of tissue pathology (score 0-12) in distal colon sections of TLR2- and TLR4-deficient mice. In addition, TLR2- but not TLR4-deficient mice cross-bred to the IL-10-deficient background develop moderate colitis, suggesting different effects of these pattern recognition receptors in regulating disease mechanisms. Proteome analysis revealed significantly regulated proteins associated with endoplasmic reticulum (ER) and mitochondrial stress responses in the epithelium. In contrast to TLR2(-/-) and IL-10XTLR2(-/-) mice, the induction of the ER-associated chaperone grp-78 was dissociated from the activation of proapoptotic caspase 3 cleavage in noninflamed TLR4(-/-) and IL10XTLR4(-/-) mice. These results suggest that ER-associated cellular stress responses play an important role in epithelial cells homeostasis leading to beneficial but also deleterious effects. We hypothesize that ER stress-associated processes in the absence of TLR2 and TLR4 differentially affect host responses and epithelial functions under conditions of genetically driven chronic intestinal inflammation.

We analyzed ATG16L1, a recently identified Crohn's disease (CD) susceptibility gene, in a large cohort with inflammatory bowel disease (IBD) including potential interactions with other IBD genes as well as factors regulating its gene expression.Genomic DNA from 2,890 Caucasians including 768 patients with CD, 507 patients with ulcerative colitis (UC), and 1,615 healthy controls was analyzed for 9 different ATG16L1 single nucleotide polymorphisms (SNPs). Genotyping included CARD15/NOD2 variants p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008 and polymorphisms in SLC22A4/OCTN1 (1672 C--T) and SLC22A5/OCTN2 (-207 G--C) as well as 10 CD-associated IL23R variants. The transcriptional regulation of ATG16L1 was studied in intestinal epithelial cells following stimulation with Toll-like receptor (TLR) ligands and proinflammatory cytokines and in a murine ileitis model and CD biopsies.All nine ATG16L1 gene variants analyzed displayed highly significant associations with CD demonstrating a CD-protective effect for the minor allele. The strongest associations were found for rs2241879 and the coding SNP rs2241880 (T300A); P= 3.6 x 10(-6) and 3.7 x 10(-6), respectively (OR 0.74, 95% CI 0.65-0.84 for both variants). The genotype-phenotype analysis revealed no significant associations. In UC, only rs6431660 was weakly disease-associated. There was no evidence for epistasis between the ATG16L1 gene and other susceptibility genes (IL23R, CARD15, SLC22A4/5). ATG16L1 mRNA expression was not upregulated in CD and murine ileitis, and was less than threefold increased in cells stimulated with proinflammatory cytokines and TLR ligands.ATG16L1 is a CD susceptibility gene without epistatic interaction with other CD susceptibility genes and is not upregulated in intestinal inflammation.

Background: Interleukin (IL)-17F, produced in IL-23R-expressing Th17 cells, is a novel member of the IL-17 cytokine family. Given the association of IL23R with inflammatory bowel disease (IBD), we characterized the role of IL-17F in IBD including its intestinal gene expression and the effect of the IL17F p.His161Arg polymorphism on disease susceptibility and phenotype of Crohn's disease (CD) and ulcerative colitis (UC). In addition, we analyzed the IL17F p.His161Arg polymorphism for potential epistasis with IL23R and NOD2/CARD15 variants. Methods: Intestinal IL-17F mRNA expression was measured by quantitative polymerase chain reaction (PCR). Genomic DNA from 1682 individuals (CD: n = 499; UC: n = 216; controls: n = 967) was analyzed for the presence of the IL17F p.His161Arg polymorphism, the 3 NOD2 variants, p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008, and 10 CD-associated IL23R variants. Results: Intestinal IL-17F mRNA expression was 4.4-fold increased in inflamed colonic lesions compared to uninflamed biopsies in CD (P = 0.016) but not in UC. However, the mean intestinal IL-17F mRNA expression was higher in UC than in CD (P < 0.0001). The IL17F p.His161Arg substitution was observed with similar frequencies in IBD patients and controls and was not associated with a certain disease phenotype, but weakly associated with a low body mass index (BMI; P = 0.009) and an earlier age of disease onset (P = 0.039) in UC. There was no evidence for epistasis between the IL17F p.His161Arg polymorphism and IBD-associated single nucleotide polymorphisms within the IL23R gene. Conclusions: Intestinal IL17F gene expression is increased in active CD. The IL17F p.His161Arg polymorphism is not associated with IBD susceptibility and has no epistatic interaction with CD-associated IL23R variants. (Inclamm Bowel Dis 2007)

Background: We analyzed the influence of Crohn's disease (CD)-associated IL23R gene variants on IL-22 that is expressed in IL-23R+ Th17 cells. Methods: IL-22 serum levels were measured in 242 CD patients and in 31 healthy controls. Subanalyses included serum levels of IL-6, TNF-α, IL-17A, IL-17F, C-reactive protein (CRP), and leukocyte count. In all patients, genotyping for 10 CD-associated IL23R single nucleotide polymorphisms (SNPs) and the 3 main CD-associated CARD15 variants was performed. Results: There was a highly significant increase in IL-22 serum expression in CD patients compared to healthy controls (P = 2.53 × 10−9). IL-22 serum levels correlated with disease activity: IL-22 levels in patients with a Crohn's disease activity index (CDAI) >150 were significantly higher than in patients with a CDAI

BACKGROUND: The IL23R gene has been identified as a susceptibility gene for inflammatory bowel disease (IBD) in the North American population. The aim of our study was to test this association in a large German IBD cohort and to elucidate potential interactions with other IBD genes as well as phenotypic consequences of IL23R variants. METHODS: Genomic DNA from 2670 Caucasian individuals including 833 patients with Crohn's disease (CD), 456 patients with ulcerative colitis (UC), and 1381 healthy unrelated controls was analyzed for 10 IL23R SNPs. Genotyping included the NOD2 variants p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008 and polymorphisms in SLC22A4/OCTN1 (1672 C-->T) and SLC22A5/OCTN2 (-207 G-->C). RESULTS: All IL23R gene variants analyzed displayed highly significant associations with CD. The strongest association was found for the SNP rs1004819 [P = 1.92x10(-11); OR 1.56; 95 % CI (1.37-1.78)]. 93.2% of the rs1004819 TT homozygous carriers as compared to 78% of CC wildtype carriers had ileal involvement [P = 0.004; OR 4.24; CI (1.46-12.34)]. The coding SNP rs11209026 (p.Arg381Gln) was protective for CD [P = 8.04x10(-8); OR 0.43; CI (0.31-0.59)]. Similar, but weaker associations were found in UC. There was no evidence for epistasis between the IL23R gene and the CD susceptibility genes CARD15 and SLC22A4/5. CONCLUSION: IL23R is an IBD susceptibility gene, but has no epistatic interaction with CARD15 and SLC22A4/5. rs1004819 is the major IL23R variant associated with CD in the German population, while the p.Arg381Gln IL23R variant is a protective marker for CD and UC.

J. Seiderer1, J. Glas1, J. Diegelmann1, G. Pasciuto1, C. Tillack1, D. Roeske2, S. Pfennig1, M. Jurgens1, A. Konrad1, H. Torok1, T. Griga3, W. Klein4, J.T. Epplen5, U. Schiemann6, T. Mussack7, P. Lohse8, B. Goke1, T. Ochsenkuhn1, M. Folwaczny9, B. Muller-Myhsok10, S. Brand1 *. 1University of Munich Klinikum Groshadern, Munich, Germany, 2Biostatistics, Max-Planck-Institute for Psychiatry, Munich-Schwabing, Munich, Germany, 3Department of Internal Medicine, Knappschaftskrankenhaus Dortmund, Dortmund, Germany, 4Department of Human Genetics, Ruhr-University, Bochum, Germany, 5Department of Human Genetics, University Bochum, Bochum, Germany, 6Department of General Internal Medicine, Inselspital Bern, Bern, Switzerland, 7Department of Surgery, LMU Munich, Munich, Germany, 8Department of Clinical Chemistry, University Hospital Munich-Grosshadern, Munich, Germany, 9Clinic for Preventive Dentistry and Parodontology, LMU Munich, Munich, Germany, 10Max-Planck-Institute for Psychiatry, Munich-Schwabing, Munich, Germany